Oesophageal Cancer Clinical Trial
Official title:
Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophageal Carcinoma Cancer on the One-Year Survival (RTEP3)
The poor prognosis in the early-stage of oesophageal carcinoma cancer is due to potential
worsening of the disease (local relapse, metastasis), to insufficient efficacy and toxicity
of actual treatments.
FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose
consumption. Then, this exam is used for pathology staging, target volume definition for RT,
and treatment efficiency few months after CRT. Our assumption is that an FDG-PET exam during
the course of CRT might be predictive of the treatment efficiency few months later.
In this study, we propose to perform 4 FDG-PET: first "PET1" before chemo-radiotherapy,
second "PET2" during the chemo-radiotherapy (see RTEP1), third and fourth "PET3" "PET4"
3month and 12 month after the end of radiotherapy.
We will investigate the performances of FDG-PET performed during CRT for the prediction of
the one-year patient heath outcome. If the predictive value of TEP2 is confirmed, we would
be able to optimize the planning treatment during the course of the therapy.
n/a
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05685862 -
Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit
|
||
| Recruiting |
NCT01795768 -
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
|
Phase 2 | |
| Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
| Recruiting |
NCT03978377 -
Cardiopulmonary Toxicity of Thoracic Radiotherapy
|
||
| Active, not recruiting |
NCT03653052 -
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
|
Phase 2 | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Terminated |
NCT01795976 -
NY-ESO-1 T Cells in OG Cancer
|
Phase 2 | |
| Recruiting |
NCT01843829 -
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
|
Phase 2 | |
| Completed |
NCT01915693 -
ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study
|
Phase 3 | |
| Completed |
NCT02382237 -
Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition
|
N/A | |
| Recruiting |
NCT04517448 -
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
|
||
| Recruiting |
NCT04232735 -
Evidence Based Information Provision to Improve Decision Making After Oesophagogastric Cancer Diagnosis (SOURCE)
|
N/A | |
| Recruiting |
NCT05642819 -
REVOLUTION Surgery (REVOLUTION Surgery)
|
||
| Recruiting |
NCT04001478 -
Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
|
||
| Recruiting |
NCT02741856 -
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05600608 -
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome
|
N/A | |
| Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
| Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06046846 -
Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer
|
N/A |